期刊文献+

膀胱移行细胞癌组织中NF-κB p65、uPA、Bcl-2的表达变化及其意义 被引量:3

Expression and significance of NF-κB p65,uPA,Bcl-2 in transitional cell carcinoma of bladder
下载PDF
导出
摘要 目的观察膀胱移行细胞癌(下称膀胱癌)组织中NF-κB p65和尿激酶型纤溶酶原激活物(uPA)及Bcl-2的表达变化,并探讨其相关性。方法采用免疫组化SP法对40例膀胱癌组织和10例正常膀胱组织中NF-κBp65、uPA、Bcl-2进行测定,分析三者与膀胱癌分级、分期、侵袭转移及复发的关系及NF-κB p65表达与uPA、Bcl-2的相关性。结果 NF-κB p65、uPA、Bcl-2在膀胱癌组织中的表达均明显高于正常膀胱组织(P<0.05);NF-κB p65和uPA与膀胱癌病理分级、分期、淋巴结转移有关(P均<0.05),Bcl-2与膀胱癌病理分级、分期有关(P<0.05),与淋巴结转移无关(P>0.05);膀胱癌组织中,NF-κB p65表达与uPA、Bcl-2表达呈正相关(r分别为0.388、0.462,P均<0.05)。结论在膀胱癌组织中NF-κB p65、uPA、Bcl-2均呈高表达,并与膀胱癌的临床病理学特征有关;NF-κB p65可能通过调控uPA、Bcl-2的表达促进膀胱癌的进展;NF-κB p65、uPA、Bcl-2可以作为判断膀胱癌侵袭性、转移及预后的生物学标志物。 Objective To observe the expression of NF-κB p65, uPA and Bcl-2 in bladder transitional cell carcinoma ( here in after referred to as bladder cancer) tissue, and explore its relevance. Methods The expression of NF-κB p65, uPA and Bcl-2 in 40 cases of bladder cancer and 10 cases of normal bladder tissue were detected by immunohistochemical technique, its relationships with pathological grade, clinical stage, invasion, metastasis, recurrence and the correlation of NF-κB p65 and uPA, Bcl-2 were analized. Results The expression of NF-κB p65, uPA, Bcl-2 in bladder cancer were significantly higher than that of normal bladder tissue ( P 〈 0.05 ) ; expression of NF-κB p65 and uPA in bladder cancer has relation to pathological grade, clinical stage, lymph node metastasis ( all P 〈 0.05 ), expression of Bcl-2 has relation to pathological grade, clinical stage ( P 〈 0.05 ) , but not to lymph node metastasis ( P 〉 0.05 ). The expression of NF-κB p65 and uPA, Bcl-2 in bladder cancer was positively correlated ( r = 0. 388, 0. 462, all P 〈 0. 05). Conclusions NF-κB p65, uPA and Bcl-2 in bladder cancer with high expression and have relation to clinicopathological characteristics of the bladder cancer. NF-κB p55 may promote the progress of bladder cancer by regulating uPA, Bcl-2. NF-κB p55, uPA and Bcl-2 can be used as biomarkers to decide transitional cell carcinoma of bladder invasion, metastasis and prognosis.
出处 《山东医药》 CAS 北大核心 2011年第46期11-13,共3页 Shandong Medical Journal
基金 江西省教育厅科学技术研究项目(GJJ09109)
关键词 膀胱肿瘤 膀胱移行细胞癌 核因子-κB P65 尿激酶型纤溶酶原激活物 BCL-2蛋白 bladder tumor transitional cell carcinoma of bladder nuclear factor kappaB p65 urokinase plasminogen activator Bcl-2
  • 相关文献

参考文献2

二级参考文献27

  • 1陈伟,陈谦学,王军民,郭熙雄,吴立权.NF-κB和uPA在人脑胶质瘤中的表达[J].中国临床神经外科杂志,2007,12(2):83-85. 被引量:4
  • 2Choong PF,Nadesapillai AP.Urokinase plasminogen activator system:a multifunctional role in tumor progression and metastasis[J].Clin Orthop Relat Res,2003(415 Suppl):S46-S58.
  • 3Crippa MP.Urokinase-type plasminogen activator[J].Int J Biochem Cell Bio,2007,39(4):690-694.
  • 4de Bock CE,Lin Z,Itoh T,et al.Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells[J].FEBS J,2005,272(14):3572-3582.
  • 5Pierga JY,Bonneton C,Magdelénat H,et al.Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor(uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients[J].Int J Cancer,2005,114(2):291-298.
  • 6Harbeck N,Kates RE,Schmitt M,et al.Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer[J].Clin Breast Cancer,2004,5(5):348-352.
  • 7Meng S,Tripathy D,Shete S,et al.uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues[J].Proc Natl Acad Sci USA,2006,103(46):17361-17365.
  • 8Minisini AM,Fabbro D,Di Loreto C,et al.Markers of the uPA system and common prognostic factors in breast cancer[J].Am J Clin Pathol,2007,128(1):112-117.
  • 9Kaneko T,Konno H,Baba M,et al.Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer[J].Cancer Sci,2003,94(1):43-49.
  • 10Tanaka N,Fukao,Ueshima S,et al.Plasminogen activator inhibitor 1 in human carcinoma tissues[J].Int J Cancer,1991,48(4):481-484.

共引文献79

同被引文献25

  • 1林称意,原野,罗卫民,郭家龙.TSLC1和CD105在食管癌组织中表达的临床意义[J].实用癌症杂志,2014,29(3):263-265. 被引量:7
  • 2Andrew AS, Gui J, Hu T, et al. Genetic polymorphisms modi- fy bladder cancer recurrence and survival in a USA population based prognostic study[J]. BJU Int, 2015, 115(2):238- 247.
  • 3Hermann GG, Mogensen K, Tort BG, et al. Outpatient diag- nostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies [J]. ScandJ UrolNephrol, 2012, 46(1):31-36.
  • 4Miloos evi c R, Milovi c N, Aleksi c P, et al. Difference in recurrence fre- quencies of norvmucle-invasive-bladder tumors deFending on optimal us- age of intravesical intmunotherapy of bacillus Calmette-Gufirin [J]. Vo- jnoanit Pregl, 2015, 72(3) :241 -246.
  • 5Mallen E, Gil P, Gil MJ. Risk groups in bladder cancer patients treated with radical cystectomy [J]. Int Braz J Urol, 2015, 41 (1) :30-39.
  • 6Netto GJ. Molecular genetics and genomics progress in urothelial blad- der cancer[J]. SeminDiamaPathol, 2013, 30(4);313 -320.
  • 7Kiss B, Skuginna V, Fleischmann A, et al. Bcl-2 predicts re sponse to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder [J]. UrolOncol, 2015, 33(4):166. e1-8.
  • 8Goyal S, Singh UR, Sharma S, et al. Correlation of mitotic in- dices, AgNor count, Ki-67 and Bcl-2 with grade and stage in papillary urothelial bladder cancer [J]. Urol J, 2014, 11(1): 1238-1247.
  • 9GolestaniEimani B, Sanati MH, Houshmand M, et al. Expres- sion and prognostic significance of bcl 2 and bax in the progres- sion and clinical outcome of transitional bladder cell carcinoma[J]. Cell J, 2014, 15(4) :356-363.
  • 10Papadopoulos EI, Yousef GM, Scorilas A. Gemcitabine im- pacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related mi- croRNAs and BCL2 family genes[J]. Tumour Biol, 2015, 36 (5) :3197-3207.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部